Literature DB >> 3120506

8-Amino-9-substituted guanines: potent purine nucleoside phosphorylase (PNP) inhibitors.

J C Sircar1, C R Kostlan, G W Pinter, M J Suto, T P Bobovski, T Capiris, C F Schwender, M K Dong, M E Scott, M K Bennett.   

Abstract

A series of 8-amino-9-substituted guanines was synthesized and their activity evaluated against human purine nucleoside phosphorylase (PNP). All compounds were found to be potent inhibitors of human PNP (IC50s: 0.17-126 microM). They were also selectively cytotoxic to MOLT-4 lymphoblasts in the presence of a nontoxic amount (10 microM) of the PNP substrate, 2'-deoxyguanosine (GdR). The most potent of these analogs, 2,8-diamino-1,9-dihydro-9-(2-thienylmethyl)-6H-purin-6-one (8-amino-9-(2-thienylmethyl)guanine; PD 119,229) has an IC50 of 0.17 microM (Ki = 0.067 microM), significantly more potent than the known standard, 8-aminoguanosine (IC50 = 1.40 microM). Thus it represents the most potent PNP inhibitor known to date when tested without limiting the concentration of inorganic phosphate.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3120506     DOI: 10.1007/bf01966482

Source DB:  PubMed          Journal:  Agents Actions        ISSN: 0065-4299


  7 in total

1.  Inhibitors of human purine nucleoside phosphorylase. Synthesis, purine nucleoside phosphorylase inhibition, and T-cell cytotoxicity of 2,5-diaminothiazolo[5,4-d]pyrimidin-7(6H)-one and 2,5-diaminothiazolo[4,5-d]pyrimidin-7(6H)-one. Two thio isosteres of 8-aminoguanine.

Authors:  J C Sircar; M J Suto; M E Scott; M K Dong; R B Gilbertsen
Journal:  J Med Chem       Date:  1986-09       Impact factor: 7.446

2.  Lymphocyte involvement in rheumatoid arthritis. Studies during thoracic duct drainage.

Authors:  H E Paulus; H I Machleder; S Levine; D T Yu; N S MacDonald
Journal:  Arthritis Rheum       Date:  1977 Jul-Aug

3.  Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.

Authors:  R B Gilbertsen; M E Scott; M K Dong; L M Kossarek; M K Bennett; D J Schrier; J C Sircar
Journal:  Agents Actions       Date:  1987-08

4.  Efficacy of total lymphoid irradiation in intractable rheumatoid arthritis. A double-blind, randomized trial.

Authors:  S Strober; A Tanay; E Field; R T Hoppe; A Calin; E G Engleman; B Kotzin; B W Brown; H S Kaplan
Journal:  Ann Intern Med       Date:  1985-04       Impact factor: 25.391

5.  Inhibitors of purine nucleoside phosphorylase, C(8) and C(5') substitutions.

Authors:  J D Stoeckler; C Cambor; V Kuhns; S H Chu; R E Parks
Journal:  Biochem Pharmacol       Date:  1982-01-15       Impact factor: 5.858

6.  Lymphapheresis in rheumatoid arthritis. A randomized trial.

Authors:  J Karsh; J H Klippel; P H Plotz; J L Decker; D G Wright; M W Flye
Journal:  Arthritis Rheum       Date:  1981-07

7.  Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity.

Authors:  E R Giblett; A J Ammann; D W Wara; R Sandman; L K Diamond
Journal:  Lancet       Date:  1975-05-03       Impact factor: 79.321

  7 in total
  1 in total

1.  Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.

Authors:  R B Gilbertsen; M E Scott; M K Dong; L M Kossarek; M K Bennett; D J Schrier; J C Sircar
Journal:  Agents Actions       Date:  1987-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.